

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER INC.,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case IPR2020-01252
Patent 8,114,833

**PATENT OWNER'S MANDATORY NOTICE INFORMATION
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner, Novo Nordisk A/S (“Novo Nordisk”), hereby files its Mandatory Notices:

I. Real Party-in-Interest (§ 42.8(b)(1))

The following real parties-in-interest are identified: Novo Nordisk A/S, Novo Nordisk Inc., Novo Holdings A/S, and Novo Nordisk Foundation.

II. Related Matters (§ 42.8(b)(2))

Patent Owner is aware of the following proceeding before the USPTO involving U.S. Patent No. 8,114,833: *Mylan Institutional LLC v. Novo Nordisk A/S*, No. IPR2020-00324. IPR2020-00324 was instituted and is currently pending.

Patent Owner is also aware of the following district court litigations involving U.S. Patent No. 8,114,833: *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-1551-CFC (D. Del.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-164 (N.D. W. Va.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc.*, No. 20-cv-747-CFC (D. Del.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc.*, 20-cv-6842-RMB-AMD (D.N.J.). Case Nos. 19-cv-1551-CFC and 20-cv-747-CFC are currently pending. Case Nos. 19-cv-164 and 20-cv-6842-RMB-AMD have been voluntarily dismissed.

U.S. Patent Application No. 16/260,204, which is pending and was filed on January 29, 2019, and U.S. Patent Application No. 16/910,945, which is pending

and was filed on June 24, 2020, both claim the benefit of U.S. Application No. 11/435,977, which is the application that issued as U.S. Patent No. 8,114,833.

III. Counsel and Service Information (§§ 42.8(b)(3) and (4))

Patent Owner identifies its lead and backup counsel as shown below:

Lead Counsel	Backup Counsel
Jeffrey J. Oelke FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) joelke@fenwick.com USPTO Reg. No. 37,409	Ryan P. Johnson <i>(pro hac vice to be sought)</i> FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) ryan.johnson@fenwick.com Laura T. Moran <i>(pro hac vice to be sought)</i> FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) laura.moran@fenwick.com

Please address all correspondence to the lead and backup counsel at the above addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic service to the e-mail addresses above for lead and backup counsel and to Novo833IPR@fenwick.com.

IV. Patent Owner Preliminary Response

Patent Owner reserves the right to file a preliminary response at a later date.

V. Patent Owner Power of Attorney

A Power of Attorney to transact all business in the United States Patent and Trademark Office in connection with above-referenced *Inter Partes* Review from Patent Owner Novo Nordisk A/S to the above-designated counsel at Fenwick & West LLP is being filed concurrently with these Mandatory Notices.

Dated: August 12, 2020

Respectfully submitted,

/Jeffrey J. Oelke/

Jeffrey J. Oelke (Reg. No. 37,409)

FENWICK & WEST LLP

902 Broadway, Suite 14

New York, NY 10010

(212) 430-2600 (tel)

(650) 938-5200 (fax)

joelke@fenwick.com

Counsel for Novo Nordisk A/S

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner's Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on August 12, 2020, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Jovial Wong
Charles B. Klein
Sharon Lin
jwong@winston.com
cklein@winston.com
slin@winston.com
PfizerIPRs@winston.com

Date: August 12, 2020

Respectfully submitted,

/ Jeffrey J. Oelke/
Jeffrey J. Oelke (Reg. No. 37,409)

Counsel for Novo Nordisk A/S